Gene Co-Expression Networks Restructured Gene Fusion in Rhabdomyosarcoma Cancers

Rhabdomyosarcoma is subclassified by the presence or absence of a recurrent chromosome translocation that fuses the FOXO1 and PAX3 or PAX7 genes. The fusion protein (FOXO1-PAX3/7) retains both binding domains and becomes a novel and potent transcriptional regulator in rhabdomyosarcoma subtypes. Many studies have characterized and integrated genomic, transcriptomic, and epigenomic differences among rhabdomyosarcoma subtypes that contain the FOXO1-PAX3/7 gene fusion and those that do not; however, few investigations have investigated how gene co-expression networks are altered by FOXO1-PAX3/7. Although transcriptional data offer insight into one level of functional regulation, gene co-expression networks have the potential to identify biological interactions and pathways that underpin oncogenesis and tumorigenicity. Thus, we examined gene co-expression networks for rhabdomyosarcoma that were FOXO1-PAX3 positive, FOXO1-PAX7 positive, or fusion negative. Gene co-expression networks were mined using local maximum Quasi-Clique Merger (lmQCM) and analyzed for co-expression differences among rhabdomyosarcoma subtypes. This analysis observed 41 co-expression modules that were shared between fusion negative and positive samples, of which 17/41 showed significant up- or down-regulation in respect to fusion status. Fusion positive and negative rhabdomyosarcoma showed differing modularity of co-expression networks with fusion negative (n = 109) having significantly more individual modules than fusion positive (n = 53). Subsequent analysis of gene co-expression networks for PAX3 and PAX7 type fusions observed 17/53 were differentially expressed between the two subtypes. Gene list enrichment analysis found that gene ontology terms were poorly matched with biological processes and molecular function for most co-expression modules identified in this study; however, co-expressed modules were frequently localized to cytobands on chromosomes 8 and 11. Overall, we observed substantial restructuring of co-expression networks relative to fusion status and fusion type in rhabdomyosarcoma and identified previously overlooked genes and pathways that may be targeted in this pernicious disease.

[1]  S. Fulda,et al.  BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis , 2018, Oncogene.

[2]  Lynette M. Smith,et al.  Examination of gene fusion status in archival samples of alveolar rhabdomyosarcoma entered on the Intergroup Rhabdomyosarcoma Study-III trial: a report from the Children's Oncology Group. , 2006, The Journal of molecular diagnostics : JMD.

[3]  F. Barr,et al.  Tumorigenesis and Neoplastic Progression High Expression of the PAX3-FKHR Oncoprotein Is Required to Promote Tumorigenesis of Human Myoblasts , 2022 .

[4]  Lynette M. Smith,et al.  Genomic and Clinical Analysis of Amplification of the 13q31 Chromosomal Region in Alveolar Rhabdomyosarcoma: A Report from the Children's Oncology Group , 2011, Clinical Cancer Research.

[5]  P. Meltzer,et al.  Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer. , 2011, Cancer research.

[6]  M. Delorenzi,et al.  Reply to S. Stegmaier et al , 2012 .

[7]  T. Triche,et al.  Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas. , 2006, Cancer research.

[8]  Kun Huang,et al.  Normalized lmQCM: An Algorithm for Detecting Weak Quasi-Cliques in Weighted Graph with Applications in Gene Co-Expression Module Discovery in Cancers , 2014, Cancer informatics.

[9]  Lynette M. Smith,et al.  Genomic and clinical analyses of 2p24 and 12q13‐q14 amplification in alveolar rhabdomyosarcoma: A report from the Children's Oncology Group , 2009, Genes, chromosomes & cancer.

[10]  H. Enterline,et al.  Rhabdomyosarcoma: A clinicopathological study and classification of 39 cases , 1958, Cancer.

[11]  M. Cieśla,et al.  MicroRNAs and epigenetic mechanisms of rhabdomyosarcoma development. , 2014, The international journal of biochemistry & cell biology.

[12]  S. Horvath,et al.  A General Framework for Weighted Gene Co-Expression Network Analysis , 2005, Statistical applications in genetics and molecular biology.

[13]  Mauro Delorenzi,et al.  PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Holly S Stevenson,et al.  Distinct methylation profiles characterize fusion-positive and fusion-negative rhabdomyosarcoma , 2015, Modern Pathology.

[15]  O. Delattre,et al.  Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Yang Xiang,et al.  Mining the tissue-tissue gene co-expression network for tumor microenvironment study and biomarker prediction , 2013, BMC Genomics.

[17]  G. Grosveld,et al.  PAX3-FOXO1 induces up-regulation of Noxa sensitizing alveolar rhabdomyosarcoma cells to apoptosis. , 2013, Neoplasia.

[18]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[19]  Sean R. Davis,et al.  GEOquery: a bridge between the Gene Expression Omnibus (GEO) and BioConductor , 2007, Bioinform..

[20]  Chang S. Chan,et al.  Mutational Landscape of the Essential Autophagy Gene BECN1 in Human Cancers , 2014, Molecular Cancer Research.

[21]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[22]  G. Getz,et al.  GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers , 2011, Genome Biology.

[23]  S. Bielack,et al.  Questionable universal validity of PAX3/FOXO1 fusion gene status as molecular marker for improvement of risk stratification in rhabdomyosarcoma therapy. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Ferrer,et al.  PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. , 2017, Cancer discovery.

[25]  M. Bittner,et al.  Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays. , 1998, Cancer research.

[26]  E. Monti,et al.  Uncovering metabolism in rhabdomyosarcoma , 2016, Cell cycle.

[27]  Cun-Quan Zhang,et al.  A new clustering method and its application in social networks , 2011, Pattern Recognit. Lett..

[28]  Edda Klipp,et al.  Supporting Text S1: Influence of cell shape, inhomogeneities and diffusion barriers in cell polarization models , 2015 .

[29]  P. Meltzer,et al.  Relationship of DNA methylation to mutational changes and transcriptional organization in fusion‐positive and fusion‐negative rhabdomyosarcoma , 2019, International journal of cancer.

[30]  G. Getz,et al.  Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusion-negative tumors. , 2014, Cancer discovery.

[31]  D. Januszkiewicz-Lewandowska,et al.  Rhabdomyosarcoma in children - current pathologic and molecular classification. , 2018, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[32]  S. Spunt,et al.  Pediatric nonrhabdomyosarcoma soft tissue sarcomas. , 2008, The oncologist.

[33]  J. Davie,et al.  New insights into signalling-pathway alterations in rhabdomyosarcoma , 2014, British Journal of Cancer.

[34]  Regulatory landscape fusion in rhabdomyosarcoma through interactions between the PAX3 promoter and FOXO1 regulatory elements , 2017, Genome Biology.

[35]  Elizabeth Stewart,et al.  Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. , 2018, Cancer cell.

[36]  Federica Conte,et al.  Network-Based Approaches to Explore Complex Biological Systems towards Network Medicine , 2018, Genes.

[37]  G. Camussi,et al.  The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway , 2015, PloS one.

[38]  J. Houghton,et al.  Pediatric rhabdomyosarcoma cell lines are resistant to Fas-induced apoptosis and highly sensitive to TRAIL-induced apoptosis. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[39]  A. Ferrari,et al.  Rhabdomyosarcoma , 2019, Nature Reviews Disease Primers.

[40]  J. Khan,et al.  PAX3–FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma , 2017, The Journal of pathology.

[41]  F. Barr,et al.  Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. , 2007, Current molecular medicine.

[42]  B. Johansson,et al.  The impact of translocations and gene fusions on cancer causation , 2007, Nature Reviews Cancer.

[43]  Yang Xiang,et al.  Weighted Frequent Gene Co-expression Network Mining to Identify Genes Involved in Genome Stability , 2012, PLoS Comput. Biol..

[44]  Peter Langfelder,et al.  Eigengene networks for studying the relationships between co-expression modules , 2007, BMC Systems Biology.

[45]  Cesare Furlanello,et al.  Gene expression profiling identifies potential relevant genes in alveolar rhabdomyosarcoma pathogenesis and discriminates PAX3‐FKHR positive and negative tumors , 2006, International journal of cancer.

[46]  F. Barr,et al.  Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma , 2018, Molecules.

[47]  Daniel J. Devine,et al.  Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. , 2018, Cancer cell.

[48]  Satoru Miyano,et al.  Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma , 2015, Nature Communications.

[49]  J. Khan,et al.  Myogenic regulatory transcription factors regulate growth in rhabdomyosarcoma , 2017, eLife.

[50]  James R. Anderson,et al.  Rhabdomyosarcoma and Undifferentiated Sarcoma in the First Two Decades of Life: A Selective Review of Intergroup Rhabdomyosarcoma Study Group Experience and Rationale for Intergroup Rhabdomyosarcoma Study V , 2001, Journal of pediatric hematology/oncology.

[51]  C. Linardic PAX3-FOXO1 fusion gene in rhabdomyosarcoma. , 2008, Cancer letters.